Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03385707 · ClinicalTrials.gov registry record
Hypoglycemia and the Gut Microbiome
A clinical trial of Hypoglycemia, sponsored by Joslin Diabetes Center.
- Active
- Registry status
- 28
- Enrollment target
- 1
- Study location
NCT03385707: Active study of Hypoglycemia, sponsored by Joslin Diabetes Center.
NCT03385707 is a study of Hypoglycemia that is active but no longer recruiting, run by Joslin Diabetes Center. The registered enrollment target is 28 participants, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03385707, a study of Hypoglycemia, is active but no longer recruiting, sponsored by Joslin Diabetes Center.
- ACTIVE NOT RECRUITING
- Registry status
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate individuals who are currently experiencing symptoms of hypoglycemia, in order to discern correlations between microbiome composition and patterns of postprandial glycemia.
Primary Outcome
Duration of hypoglycemia will be assessed by: (1) the number of minutes per day with hypoglycemia, defined as sensor glucose \<70 mg/dl, and (2) the number of minutes per day of severe hypoglycemia, defined as sensor glucose \<55 mg/dl. Data will be captured for the entire 24 hour period as well as day and night subsets.
Conditions Studied
Study Locations (1)
Massachusetts
- Joslin Diabetes Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2026-11-01 |
What the registry record for NCT03385707 still lists
NCT03385707 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Hypoglycemia appearing as the primary indexed condition, and to 0 interventions.
NCT03385707 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03385707 about?
NCT03385707 is a clinical study titled "Hypoglycemia and the Gut Microbiome". This study is designed to evaluate individuals who are currently experiencing symptoms of hypoglycemia, in order to discern correlations between microbiome composition and patterns of postprandial glycemia.
What is the current status of trial NCT03385707?
This trial is currently active not recruiting. The enrollment target is 28 participants. The study started on 2019-02-07. Estimated completion is 2026-11-01.
What conditions does trial NCT03385707 study?
This clinical trial studies the following conditions: Hypoglycemia.
Who is sponsoring clinical trial NCT03385707?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03385707 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03385707's enrollment target sits among peer trials
28 25th of 40 higher than 15 of 40 other Hypoglycemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoglycemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia
RECRUITING
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
RECRUITING · NA
-
Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes
RECRUITING · NA
-
Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI